Angiotensin–neprilysin inhibition in <i>de novo</i> heart failure – starting off strong

Bhatt, Ankeet S.; Vaduganathan, Muthiah; Butler, Javed

doi:10.1002/ejhf.1675

Cited by 3 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Comparison of Sacubitril-Valsartan versus Enalapril on Effect on NT-proBNP in Patients Stabilized for an Acute Heart Failure Episode (PIONEER-HF) and TReatment initiation with sacubitril/valsartan in heart failure patieNtS with reduced ejection-fracTion hospitalised for an acute decOmpensation eveNt (TRANSITION) trials demonstrated the safety, improved treatment adherence, attainment of target doses, and on post hoc analysis, improvement in clinical outcomes when GDMT is initiated during hear failure hospitalization. [14][15][16][17] In PARA-DIGM-HF and TRANSITION, 29 and 34.4% of patients had de novo heart failure, and 52.1 and 24% were ACEi/ ARB-naive, respectively. De novo heart failure was an independent predictor of success of up-titration of sacubitril-valsartan, demonstrating the importance of up-front initiation of GDMT for patients with HFrEF.…”

Section: Role and Timing Of Guideline-directed Medical Therapy In Pat...mentioning

confidence: 99%

Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure

Straw

McGinlay

Gierula

et al. 2021

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

Section: Role and Timing Of Guideline-directed Medical Therapy In Pat...mentioning

confidence: 99%

Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure

Straw

McGinlay

Gierula

et al. 2021

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

“…Most recently this paradigm shift has been explored with sacubatril-valsartan. The Comparison of Sacubitril-Valsartan versus Enalapril on Effect on NT-proBNP in Patients Stabilized for an Acute Heart Failure Episode (PIONEER-HF) and TReatment initiation with sacubitril/valsartan in heart failure patieNtS with reduced ejection-fracTion hospitalised for an acute decOmpensation eveNt (TRANSITION) trials demonstrated the safety, improved treatment adherence, attainment of target doses and, on post-hoc analysis, improvement in clinical outcomes when GDMT is initiated during HF hospitalisation [14][15][16][17] . In PARADIGM-HF and TRANSITION 29% and 34.4% of patients had de novo HF, and 52.1% and 24% were ACE-inhibitor/ARB naïve, respectively.…”

Section: Role and Timing Of Gdmt In Patients With Hfrefmentioning

confidence: 99%

Impact of QRS duration on left ventricular remodelling and survival in patients with chronic heart failure

Straw

McGinlay

Gierula

et al. 2020

Preprint

View full text Add to dashboard Cite

Background In patients with chronic heart failure, QRS duration is a consistent predictor of poor outcomes. It has been suggested that for indicated patients, cardiac resynchronisation therapy (CRT) could come sooner in the treatment algorithm, perhaps in parallel with the attainment of optimal guideline-directed medical therapy (GDMT). We investigated differences in left ventricular (LV) remodelling in those with narrow QRS (NQRS) compared to wide QRS (WQRS) in the absence of CRT, whether an early CRT strategy resulted in unnecessary implants and the effect of early CRT on outcomes. Methods and results Our cohort consisted of 214 consecutive patients with LV ejection fraction (LVEF) [?]35% who underwent repeat echocardiography 1-year after enrolment. Of these, 116 patients had NQRS, and 98 had WQRS of whom 40 received CRT within 1-year and 58 did not. In the absence of CRT patients with WQRS had less LV reverse remodelling compared to those with NQRS, with differences in ΔLVEF (+9% vs 2 %, p<0.001), ΔLV end-diastolic diameter (-2mm vs -1mm, p=0.095) and ΔLV end-systolic diameter (-4.5mm vs -2mm, p=0.038). LVEF was more likely to improve by [?]10% if patients had NQRS or received CRT (p=0.08). Thirteen (24%) patients with WQRS achieved an LVEF >35% in the absence of CRT, however none achieved >50%. Conclusions A strictly linear approach to HF therapy might lead to delays to optimal treatment in those patients with the most to gain from CRT and the least to gain from GDMT.

show abstract

Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κB pathway in cardiomyocytes

Xiao¹,

Wang²,

Li³

et al. 2022

Archives of Biochemistry and Biophysics

View full text Add to dashboard Cite

Angiotensin–neprilysin inhibition in de novo heart failure – starting off strong

Cited by 3 publications

References 12 publications

Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure

Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure

Impact of QRS duration on left ventricular remodelling and survival in patients with chronic heart failure

Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κB pathway in cardiomyocytes

Contact Info

Product

Resources

About